Zobrazeno 1 - 10
of 311
pro vyhledávání: '"MDM2 inhibitor"'
Autor:
Wei Chen, Kai-Bin Yang, Yuan-Zhe Zhang, Zai-Shan Lin, Jin-Wei Chen, Si-Fan Qi, Chen-Fei Wu, Gong-Kan Feng, Da-Jun Yang, Ming Chen, Xiao-Feng Zhu, Xuan Li
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-20 (2024)
Abstract Background High expression of ubiquitin ligase MDM2 is a primary cause of p53 inactivation in many tumors, making it a promising therapeutic target. However, MDM2 inhibitors have failed in clinical trials due to p53-induced feedback that enh
Externí odkaz:
https://doaj.org/article/36aa2479810046219abd7234f4f5e8a9
Publikováno v:
Zhongliu Fangzhi Yanjiu, Vol 50, Iss 3, Pp 243-248 (2023)
Objective To investigate the effect of MDM2 inhibitor RG-7388 on the proliferation, cell cycle, and apoptosis of diffuse large B-lymphoma (DLBCL) cells. Methods DLBCL cell strains SUDHL2 and HBL1 were treated with 2, 4, and 8 μmol/LRG7388, respectiv
Externí odkaz:
https://doaj.org/article/f0e8b1e502a5443db82bd41fc21bb294
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Qinwei Chen, Suqi Deng, Manman Deng, Yuanfei Shi, Mengya Zhong, Lihong Ding, Yuelong Jiang, Yong Zhou, Bing Z. Carter, Bing Xu
Publikováno v:
Experimental Hematology & Oncology, Vol 11, Iss 1, Pp 1-4 (2022)
Abstract Dysregulation of MDM2, a p53 negative regulator, frequently occurs in acute myeloid leukemia (AML) and is associated with unfavorable prognoses, rendering the p53-MDM2 axis an attractive target for the development of small-molecule inhibitor
Externí odkaz:
https://doaj.org/article/c1fbba5b8da04b61859915b7ecb0f9dd
Autor:
Lucia Haronikova, Ondrej Bonczek, Pavlina Zatloukalova, Filip Kokas-Zavadil, Martina Kucerikova, Philip J. Coates, Robin Fahraeus, Borivoj Vojtesek
Publikováno v:
Cellular & Molecular Biology Letters, Vol 26, Iss 1, Pp 1-33 (2021)
Abstract Since the discovery of the first MDM2 inhibitors, we have gained deeper insights into the cellular roles of MDM2 and p53. In this review, we focus on MDM2 inhibitors that bind to the p53-binding domain of MDM2 and aim to disrupt the binding
Externí odkaz:
https://doaj.org/article/d1e17d5c51ce4f04a150f6d6747e8079
Autor:
Jiahao Hu, Jiasheng Cao, Win Topatana, Sarun Juengpanich, Shijie Li, Bin Zhang, Jiliang Shen, Liuxin Cai, Xiujun Cai, Mingyu Chen
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-19 (2021)
Abstract TP53 is a critical tumor-suppressor gene that is mutated in more than half of all human cancers. Mutations in TP53 not only impair its antitumor activity, but also confer mutant p53 protein oncogenic properties. The p53-targeted therapy appr
Externí odkaz:
https://doaj.org/article/f2ce447aca4d45ed9ede8c857dc83454
Autor:
Erika Rimondi, Elisabetta Melloni, Arianna Romani, Veronica Tisato, Fabio Casciano, Gian Matteo Rigolin, Daniela Milani, Claudio Celeghini, Giorgio Zauli, Paola Secchiero, Rebecca Voltan
Publikováno v:
Current Oncology, Vol 28, Iss 4, Pp 2439-2451 (2021)
In B-chronic lymphocytic leukemia (B-CLL), the interaction between leukemic cells and the microenvironment promotes tumor cell survival. The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib is one of the first-in-class molecules for the treatment
Externí odkaz:
https://doaj.org/article/5f530f4e178242669dbc74f8c127f8fc
Publikováno v:
Molecules, Vol 28, Iss 9, p 3912 (2023)
The mutation or function loss of tumour suppressor p53 plays an important role in abnormal cell proliferation and cancer generation. Murine Double Minute 2 (MDM2) is one of the key negative regulators of p53. p53 reactivation by inhibiting MDM2–p53
Externí odkaz:
https://doaj.org/article/bf23bf1900654eeaabdf53b86eb3f5a9
Autor:
Seyed Pairawan, Ming Zhao, Erkan Yuca, Allen Annis, Kurt Evans, David Sutton, Luis Carvajal, Jian-Guo Ren, Solimar Santiago, Vincent Guerlavais, Argun Akcakanat, Coya Tapia, Fei Yang, Priya Subash Chandra Bose, Xiaofeng Zheng, Ecaterina Ileana Dumbrava, Manuel Aivado, Funda Meric-Bernstam
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-15 (2021)
Abstract Background MDM2/MDMX proteins are frequently elevated in hormone receptor-positive (ER+) breast cancer. We sought to determine the antitumor efficacy of the combination of ALRN-6924, a dual inhibitor of MDM2/MDMX, with chemotherapy in ER+ br
Externí odkaz:
https://doaj.org/article/c251cacd8a6e4763988dbd3811b83598
Autor:
Meng Wu, Jingyi Cui, Huimin Hou, Ying Li, Shengjie Liu, Li Wan, Lili Zhang, Wei Huang, Gaoyuan Sun, Jingchao Liu, Pengfei Jin, Shunmin He, Ming Liu
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: The inactivation of tumor-suppressor p53 plays an important role in second generation anti-androgens (SGAs) drug resistance and neuroendocrine differentiation in castration-resistant prostate cancer (CRPC). The reactivation of p53 by bloc
Externí odkaz:
https://doaj.org/article/2de0b5c6bb834818ac4ca1699de0712c